Develop a new therapeutic approach for Parkinson’s disease.
In the perspective of developing a new therapeutic approach, B&A Therapeutics has applied for an international patent for the use of a diuretic, Bumetanide, in the treatment of Parkinson’s disease. Following the encouraging results obtained during a pilot study conducted in 4 patients with Parkinson’s disease, B&A Therapeutics is looking for investors in order to set up a phase II clinical trial in eight French centers to confirm the efficacy of the molecule it develops in the treatment of this pathology.
Connect fundamental and clinical research.
In collaboration with researchers from the Mediterranean Institute of Neurobiology (Inmed, Marseille), B&A Therapeutics works on studying early electrophysiological signs in basal ganglia of Parkinson’s disease rodent models. We have identified potential therapeutic targets on which we could act to block electrophysiological signatures of the disease. Based on these observations, we have conducted a pilot study in 4 patients and shown that Bumetanide reduces the severity of some motor symptoms, notably gait and freezing (Damier P. et al., 2016). Since the molecule has few side effects, these observations have led B&A Therapeutics to seek funding in order to conduct, in parallel with the experimental work, a broader clinical trial on 60 patients in French centers that specialize in the treatment of Parkinson’s disease.
CEO of B&A Therapeutics, Co-founder, Researcher expert on Neuroscience
Physiologist and biophysicist, Yehezkel Ben-Ari has made seminal discoveries on brain developmental sequences, epilepsies and anoxic insults… He has described, with his...
En savoir plus
CEO of B&A Therapeutics, Co-founder, Researcher expert on Neuroscience
Physiologist and biophysicist, Yehezkel Ben-Ari has made seminal discoveries on brain developmental sequences, epilepsies and anoxic insults… He has described, with his...
En savoir plus
Co-founder, Consultant expert on preclinical and clinical development
Denis Ravel is the founder of Initial R&D Consulting, a consulting firm accompanying young biotechnology companies in preclinical and clinical development of small...
En savoir plus
Co-founder, Child psychiatrist specialized in autism spectrum disorders
Resident in psychiatry (Paris, France) and then clinical head in child psychiatry (Brest, France), Eric Lemonnier is a hospital practitioner and has obtained...
En savoir plus
Co-founder, Neurologist specialized on Parkinson’s disease and related syndromes
Philippe Damier has been Professor of Neurology at the University Hospital Center (UHC) of Nantes since 1999. He received clinical and scientific...
En savoir plus
Co-founder, Researcher specialized in Parkinson’s disease
Constance Hammond is an emeritus Research Director at INSERM attached to the Mediterranean Institute of Neurobiology (Inmed, France). She has acquired an extensive experience in...
En savoir plus
Co-founder, Neurologist specialized on Parkinson’s disease
En savoir plus
Co-founder, Researcher specialized on brain imaging
En savoir plus
Co-fondateur, Consultant expert en développement préclinique et clinique
Denis Ravel est le fondateur d’Initial R&D Consulting, une société de conseil accompagnant de jeunes entreprises de biotechnologie dans le développement préclinique et...
En savoir plus
Co-fondateur, Consultant expert en développement préclinique et clinique
Denis Ravel est le fondateur d’Initial R&D Consulting, une société de conseil accompagnant de jeunes entreprises de biotechnologie dans le développement préclinique et...
En savoir plus
Co-fondateur, Consultant expert en développement préclinique et clinique
Denis Ravel est le fondateur d’Initial R&D Consulting, une société de conseil accompagnant de jeunes entreprises de biotechnologie dans le développement préclinique et...
En savoir plus
Co-fondateur, Consultant expert en développement préclinique et clinique
Denis Ravel est le fondateur d’Initial R&D Consulting, une société de conseil accompagnant de jeunes entreprises de biotechnologie dans le développement préclinique et...
En savoir plus